RESEARCH MONOGRAPH · KDC-MN-376

Riluzole

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

72/100

Approved ALS drug with a quieter second life in mood and anxiety research that's worth tracking

Riluzole is one of those approved drugs that keeps showing up where you don't expect it. Officially it's the only disease-modifying ALS therapy that's been on the market for thirty years, with a survival benefit of roughly three months. Modest. Real. The mechanism story is messier than the label suggests: it blocks persistent sodium channels, reduces glutamate release, potentiates glutamate uptake by EAAT2, and has GABA-A potentiating activity at higher concentrations. It's not a clean monotarget compound. Which is probably why it works at all in ALS, where the pathology is heterogeneous.

What we like is the off-label psychiatry signal. Mathew, Sanacora, and the Yale group have run small open-label and controlled studies in treatment-resistant depression, OCD, and GAD showing meaningful responder rates at 100 to 200 mg/day. The mechanism makes sense if you buy the glutamatergic theory of depression, which after a decade of ketamine work most of us reluctantly do. Riluzole isn't ketamine. It's a slower, more chronic glutamatergic modulator, and the response curves look slower too.

The catch is hepatotoxicity. Transaminase elevations are common, frank hepatitis is rare but real, and that's the main reason the off-label psychiatry use never went mainstream. The other reason is that the patent cliff hit a long time ago and nobody was going to fund a phase 3 for depression when generic riluzole is the same molecule for cents.

Sourcing as a research chemical is straightforward, riluzole is a small heterocycle, HPLC purity from competent suppliers is reliably 98 plus, and stability in solid form is good. Solubility in water is the annoying part. DMSO or ethanol stock then dilute.

For research, it's the tool compound of choice when you want chronic glutamate dampening without NMDA antagonism. There's a phase 2 program for ataxia (SCA) that read out positive a few years back. Watch that space, the prodrug troriluzole has more drug-like properties and might be where this story actually goes commercially.

Evidence: 78
Mechanism: 72
Reliability: 70
Safety: 65
Sourcing: 80
Value: 75
Signal: 68
Staying power: 70

Plain-language summary Intrigue 72 / 100

Riluzole was the first FDA-approved drug for ALS, cleared in 1995 and the only option until edaravone in 2017. It hits glutamate signaling from several angles at once: it blocks sodium channels (cutting glutamate release from nerve terminals), antagonizes AMPA and kainate receptors on the receiving end, and modestly potentiates GABA. Together these knock down the excitotoxic overdrive that researchers think kills motor neurons in ALS. The clinical effect is honest but small, extending median survival by roughly two to three months. That said, the benefit shows up consistently across trials, which matters. Off-label work has tested it in depression (inspired by ketamine's glutamate-targeting success), generalized anxiety, and OCD. Reference glutamate-release inhibitor in neuropharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Glutamate release inhibitor / sodium channel blocker

A benzothiazole glutamate release inhibitor with sodium channel block; the first FDA-approved drug for amyotrophic lateral sclerosis.

Abstract

Riluzole (6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; CAS 1744-22-5; molecular formula C8H5F3N2OS; molecular weight 234.20) is a benzothiazole compound developed at Rhone-Poulenc and approved by the FDA in 1995 (Rilutek) for amyotrophic lateral sclerosis. The compound was the first ALS-approved drug and remained the only one until edaravone in 2017. Mechanism is multifactorial: state-dependent voltage-gated sodium channel inhibition (reducing glutamate release from presynaptic terminals), AMPA and kainate receptor antagonism (postsynaptic glutamate effect), and modest GABA-A potentiation. The combined glutamate-reducing activity addresses the excitotoxicity hypothesis of ALS pathogenesis. Plasma half-life is approximately 12 hours; metabolism is via CYP1A2. The clinical effect in ALS is modest (median survival extension approximately 2 to 3 months) but consistent across trials. Off-label use in major depressive disorder (where ketamine's NMDA mechanism inspired interest in glutamate modulators), generalized anxiety disorder, and OCD has been investigated. Used as the canonical glutamate release inhibitor in research.

Mechanism of action

State-dependent sodium channel block (reducing presynaptic glutamate release); AMPA/kainate antagonism; modest GABA-A potentiation. Multi-target glutamate modulator.

Reported research dose ranges

Clinical 50 mg in the published literature.

References

Bensimon G, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994.
Lacomblez L, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996.
Pittenger C, et al. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-376

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Riluzole

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs